Who are Renacidin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taurolin, Revasc, Argatroban, Angiomax, Refludan, Calcium Disodium Versenate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/citric-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Renacidin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renacidin (CITRIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-coagulant. Area: Neuroscience.

marketed Anti-coagulant Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Renacidin (CITRIC ACID) — Baxter. Renacidin works by inhibiting the formation of calcium oxalate crystals in the urine, which can help prevent kidney stones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Renacidin TARGET	CITRIC ACID	Baxter	marketed	Anti-coagulant		1982-01-01
Taurolin	TAUROLIDINE		marketed	Anti-coagulant [EPC]		2023-01-01
Revasc	DESIRUDIN	Marathon Pharms Llc	marketed	Anti-coagulant	Prothrombin	2003-01-01
Argatroban	ARGATROBAN	Hikma Pharm Co Ltd	marketed	Anti-coagulant [EPC]	Prothrombin	2000-01-01
Angiomax	BIVALIRUDIN	Novartis	marketed	Anti-coagulant [EPC]	thrombin	2000-01-01
Refludan	LEPIRUDIN		marketed	Anti-coagulant	Prothrombin	1998-01-01
Calcium Disodium Versenate	EDETIC ACID	Medicis	marketed	Anti-coagulant	Amyloid beta A4 protein	1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-26 — Argatroban · 7687516 · Formulation · US
2027-09-26 — Argatroban · 7589106 · Formulation · US
2028-10-10 — Renacidin · 8450338 · US
2028-10-10 — Renacidin · 8481083 · US
2033-03-15 — Renacidin · 11439610 · US
2033-03-15 — Renacidin · 11337989 · US
2033-03-15 — Renacidin · 10568855 · US
2034-06-23 — Renacidin · 10624879 · US
2034-06-23 — Renacidin · 11191753 · US
2034-06-26 — Renacidin · 9827231 · US

Sponsor landscape (Anti-coagulant class)

· 1 drug in this class
Baxter · 1 drug in this class
Fresenius Kabi · 1 drug in this class
Marathon Pharms Llc · 1 drug in this class
Medicis · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Renacidin — Competitive Intelligence Brief. https://druglandscape.com/ci/citric-acid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing